Richmond Pharmacology is pleased to confirm our attendance at The Liver Meeting 2025, hosted by the American Association for the Study of Liver Diseases (AASLD), taking place in Washington, DC, from 7th –11th November.
Representing Richmond at The Liver Meeting:
James Rickard, Chief Scientific Officer
James looks forward to engaging with industry and academic partners to discuss Richmond’s expertise in:
• Early-phase hepatology and metabolic liver disease trials
• First-in-human and dose-ranging studies
• Non-invasive biomarkers and digital health integration
• Regulatory strategy and multi-regional trial delivery
• Patient-focused approaches in complex liver studies
If you’re attending AASLD 2025 and seeking a clinical development partner in liver disease research, get in touch to arrange a meeting with James: info@richmondpharmacology.com
#Red4Research is a global initiative that recognises the essential role of clinical research in improving treatment, outcomes, and the future of medicine.
Richmond Pharmacology will attend BioJapan 2025 in Yokohama, represented by their leadership team. The event focuses on early-phase trials, UK–Japan collaboration, regulatory strategy, bridging studies, and adaptive trial models.
By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.
.svg){kind=small}
-min.jpg)
.jpg)
